This trial will test if a new drug is effective and safe. Half the participants will receive the drug and half will receive a placebo. The trial is double-blind, meaning neither the participants nor the researchers will know who is receiving the drug or the placebo.
1 Primary · 1 Secondary · Reporting Duration: The time of providing written informed consent until 30 days after the last dose of study drug
Experimental Treatment
Non-Treatment Group
56 Total Participants · 2 Treatment Groups
Primary Treatment: SRP-3D (diethylamide) · Has Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 18 - 55 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Florida | 50.0% |
New York | 50.0% |
18 - 65 | 100.0% |
Quotient Sciences-Miami, Inc. | 100.0% |
Met criteria | 100.0% |
Phone Call | 100.0% |